NCT07946783
A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria changed
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of adverse events
Timeframe: Day 1 to Day 21
Secondary (4)
ZL65 Pharmacokinetics (PK):Cmax
ZL65 Pharmacokinetics (PK):Tmax
ZL65 Pharmacokinetics (PK):AUC0-t
ZL65 Pharmacokinetics (PK):t1/2
Arms and interventions
Single-ascending Dose (SAD) study and Food Effect (FE) studyExperimental
Multiple-ascending Doses (MAD) studyExperimental
Obesity with cardiovascular risk studyExperimental
Drugs: Single-ascending Dose (SAD) study and Food Effect (FE) study, Multiple-ascending Doses (MAD) study, Obesity with cardiovascular risk study
Sites
1 site in 1 country
- Nucleus Network Pty Ltd Commercial RoadMelbourne, Australia